Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma
Status:
Not yet recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This is a 2-part multicenter Phase 1b study designed to test icapamespib in patients with
recurrent brain lesions.
Part 1 of the trial will be a standard 3 by 3 dose escalation design where different doses
are examined. Part 2 will be a dose expansion cohort to further evaluate the recommended
Phase 2 dose (RP2D). The RP2D is defined as the dose level recommended for further clinical
study, or the highest dose tested.